12/9
12:27 am
imcr
Immunocore Holdings plc (IMCR) Asserts Pipeline Development and Strong Commercial Performance [Yahoo! Finance]
Medium
Report
Immunocore Holdings plc (IMCR) Asserts Pipeline Development and Strong Commercial Performance [Yahoo! Finance]
11/27
06:40 pm
imcr
Immunocore (IMCR) Q2 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Immunocore (IMCR) Q2 2025 Earnings Call Transcript [Yahoo! Finance]
11/18
09:00 am
imcr
The Galien Foundation Announces 2025 Prix Galien Bridges Awards Nominees for "Best Bridge-Builder Institution," "Best Biomedical Product," "Best Medical Technology/AI Advances in Human Health," "Best Product for Rare/Orphan Diseases," and "Best Public Sec
Low
Report
The Galien Foundation Announces 2025 Prix Galien Bridges Awards Nominees for "Best Bridge-Builder Institution," "Best Biomedical Product," "Best Medical Technology/AI Advances in Human Health," "Best Product for Rare/Orphan Diseases," and "Best Public Sec
11/10
01:48 pm
imcr
Immunocore (NASDAQ:IMCR) had its price target raised by analysts at Morgan Stanley from $34.00 to $36.00. They now have an "equal weight" rating on the stock.
Low
Report
Immunocore (NASDAQ:IMCR) had its price target raised by analysts at Morgan Stanley from $34.00 to $36.00. They now have an "equal weight" rating on the stock.
11/10
07:00 am
imcr
Immunocore to present at upcoming investor conferences
Medium
Report
Immunocore to present at upcoming investor conferences
11/9
08:23 am
imcr
Immunocore Holdings plc (NASDAQ:IMCR) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
Low
Report
Immunocore Holdings plc (NASDAQ:IMCR) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
11/8
01:12 am
imcr
Low
Report
11/7
11:28 pm
imcr
Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst [Seeking Alpha]
Low
Report
Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst [Seeking Alpha]
11/7
08:00 am
imcr
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
Medium
Report
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
11/6
07:00 am
imcr
Immunocore reports third quarter financial results and provides a business update
Low
Report
Immunocore reports third quarter financial results and provides a business update
11/4
05:49 am
imcr
Immunocore (NASDAQ:IMCR) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.
Low
Report
Immunocore (NASDAQ:IMCR) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.
10/31
07:19 am
imcr
Immunocore (NASDAQ:IMCR) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating on the stock.
Low
Report
Immunocore (NASDAQ:IMCR) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating on the stock.
10/22
01:57 pm
imcr
Immunocore (NASDAQ:IMCR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Medium
Report
Immunocore (NASDAQ:IMCR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
10/8
12:25 pm
imcr
Immunocore (NASDAQ:IMCR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Immunocore (NASDAQ:IMCR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.